Journey Medical Corp. (NASDAQ: DERM) Rises Sharply in 5/15 Early Trading Session

Stock Information for Journey Medical Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Journey Medical Corporation

Journey Medical Corporation Announces Emrosi(TM) Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference
Journey Medical Corporation Announces Emrosi(TM) Featured on "The Balancing Act" Airing on Lifetime TV
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
Journey Medical Corporation Launches Emrosi(TM) (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.